Summary
Bristol-Myers Squibb Company (BMY) filed an amended quarterly report (10-Q/A) on March 27, 2003, for the period ending March 31, 2002. This filing primarily concerns the restatement of previously issued financial statements due to significant accounting errors related to revenue recognition for sales to U.S. pharmaceutical wholesalers. The company identified a substantial buildup of wholesaler inventories, primarily in 2000 and 2001, caused by sales incentives offered to meet quarterly sales projections. This led to a determination that certain sales should have been accounted for under the consignment model rather than recognized upon shipment. The restatement impacted prior periods, reducing reported net earnings and earnings per share for 1999-2001, but increasing them for the first half of 2002. The company has undertaken significant efforts to strengthen internal controls, revise its budgeting process, and improve communication and oversight to prevent recurrence. PricewaterhouseCoopers LLP identified two "material weaknesses" in the company's accounting and financial reporting processes. Investors should pay close attention to the significant impact of these accounting adjustments and the ongoing efforts to remediate internal control deficiencies.
Key Highlights
- 1Restatement of financial statements for the three years ended December 31, 2001, and interim periods due to errors in revenue recognition for certain U.S. pharmaceutical wholesaler sales.
- 2Identification of a substantial buildup of wholesaler inventories, primarily in 2000-2001, attributed to sales incentives.
- 3Adoption of the consignment model for certain sales to two major U.S. wholesalers, impacting the timing of revenue recognition.
- 4The restatement resulted in a net reduction of $411 million in net earnings for 2001, $240 million for 2000, and $366 million for 1999.
- 5Two "material weaknesses" were identified by independent auditors related to accounting and public financial reporting of significant matters and management oversight.
- 6The company has implemented remedial actions, including hiring new finance leadership, creating a chief compliance officer role, and revising its budgeting and control processes.
- 7Significant legal proceedings are ongoing, including antitrust litigation related to TAXOL® and BUSPAR, with proposed settlements impacting financial reserves.